Silence Therapeutics (SLN) Income from Continuing Operations (2024 - 2026)
Silence Therapeutics (SLN) posted Income from Continuing Operations of 14957000.0 for Q1 2026, down 27.08% sequentially from 11770000.0 in Q4 2025, and up 47.57% YoY from 10135221.01 in Q1 2025.
Silence Therapeutics (SLN) Income from Continuing Operations (2024 - 2026) Analysis & Trends
Silence Therapeutics has reported Income from Continuing Operations for 3 years, with the latest figure at 14957000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 47.57% year-over-year to 14957000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 75039000.0 (down 25.98% YoY) and the FY2025 annual result came in at 88612000.0, down 165.72% from the prior year.
- Income from Continuing Operations fell to 14957000.0 in Q1 2026 per SLN's latest filing, from 11770000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 24263000.0 in Q4 2024 and troughed at 35544000.0 in Q3 2024.
- A 3-year average of 15213000.0 and a median of 19755000.0 in 2024 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2025 and 2026: Income from Continuing Operations tumbled 1134.0% in 2025, then jumped 47.57% in 2026.
- Over 3 years, Income from Continuing Operations stood at 24263000.0 in 2024, then slumped by 148.51% to 11770000.0 in 2025, then dropped by 27.08% to 14957000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 14957000.0, 11770000.0, and 20958000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Silence Therapeutics | 648.22 Mn | 576.12 Mn | - | -12.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -12.27 Mn |
| Mar 31, 2026 | -14.96 Mn |
| Dec 31, 2025 | -11.77 Mn |
| Sep 30, 2025 | -20.96 Mn |
| Jun 30, 2025 | -27.35 Mn |
| Mar 31, 2025 | -28.53 Mn |
| Dec 31, 2024 | 24.26 Mn |
| Sep 30, 2024 | -35.54 Mn |
| Jun 30, 2024 | -19.76 Mn |
| Mar 31, 2024 | -2.31 Mn |